← Back to Home

UK Lowers Age Eligibility for Casgevy Gene-Editing Therapy to Five

For children who have endured episodes of pain or repeated blood transfusions from an early age, the new approval offers an opportunity for earlier treatment. However, cell collection, bone marrow conditioning and inpatient care remain necessary parts of the treatment process.

By SURL BioNews

For children with severe inherited blood disorders, childhood can involve intense pain, anaemia and repeated blood transfusions. The UK has now lowered the age eligibility for the gene-editing therapy Casgevy from 12 and older to five and older, giving eligible younger patients another treatment option.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced on October 30 that it had expanded the marketing authorisation for Casgevy (exagamglogene autotemcel) to cover severe sickle cell disease and transfusion-dependent β-thalassaemia. The change was approved on October 29; reports published by Open Access Government and Mirage News on the day of the announcement also confirmed the lower age threshold, although patients must still meet other treatment eligibility criteria.

Both diseases involve abnormalities in haemoglobin that affect red blood cells’ ability to carry oxygen, but they impose different disease burdens. Severe sickle cell disease can cause intense pain, anaemia and life-threatening infections, while patients with transfusion-dependent β-thalassaemia need ongoing blood transfusions to meet their bodies’ needs.

Treatment with Casgevy begins with the patient’s own cells: blood-forming stem cells are collected, genetically edited in a laboratory and then infused back into the body. Before the infusion, patients must undergo conditioning to prepare for the modified cells to establish blood-forming function in the bone marrow. They may also need to remain in hospital afterwards while waiting for the cells to gradually take effect.

Lowering the age threshold therefore extends the care needs associated with the treatment process to younger children. Related side effects listed by the MHRA include nausea, fatigue, fever and an increased risk of infection. For families, the additional treatment opportunity also means needing to understand the burden of the entire treatment process.

The MHRA said the approval was based on an assessment of evidence on safety, quality and efficacy, and that monitoring would continue. However, the announcement did not specify the number of younger patients in trials, efficacy rates or follow-up duration, and the government release republished by Mirage News did not provide additional clinical results. What can currently be confirmed is the expanded indication; the specific benefits and long-term risks for children still need to be assessed using more complete trial and follow-up data.

References

  1. MHRA
  2. Open Access Government
  3. Mirage News